
Post-pandemic spike in adult ADHD meds prompts clinician concern
A Canadian CMAJ study finds adult ADHD stimulant prescriptions more than doubled since the start of the COVID-19 era, with a 2024 monthly rate of 10.4 per 1,000 people. The increase is strongest among 25–34-year-olds and women, and the time from first ADHD visit to prescription shortened, suggesting greater access via telehealth and primary-care prescribing. While this may reflect better treatment access, experts warn it could reflect overdiagnosis or rushed evaluations, underscoring the need for thorough assessment.













